[{"id":"167a669a-83f9-4f87-96c0-117a2b58607f","acronym":"KEYNOTE-C86","url":"https://clinicaltrials.gov/study/NCT04993677","created_at":"2021-08-06T13:53:23.272Z","updated_at":"2025-02-25T16:16:35.955Z","phase":"Phase 2","brief_title":"A Study of SEA-CD40 Given With Other Drugs in Cancers","source_id_and_acronym":"NCT04993677 - KEYNOTE-C86","lead_sponsor":"Seagen Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • cifurtilimab (SEA-CD40)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 01/03/2024","primary_completion_date":" 01/03/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-22"}]